Mendus Q2 2024: Catalysts are coming closer, solid funding position - Redeye
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

Mendus Q2 2024: Catalysts are coming closer, solid funding position - Redeye

{newsItem.title}

Redeye provides its comment on Mendus’ Q2 2024 report. Data recently presented at EHA and ESMO Gyn confirmed vididencel’s mechanism of action. Further, the company will deliver readouts from ADVANCE II, CADENCE, and ALISON in the coming 12-18 months. Its estimated funding runway extends past several of these catalysts. We do some housekeeping in our model and valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/1034365/mendus-q2-2024-catalysts-are-coming-closer-solid-funding-position?utm_source=finwire&utm_medium=RSS

Nyheter om Mendus

Läses av andra just nu

Om aktien Mendus

Senaste nytt